Meiyouheng® is the commercial brand name of Becotatug Vedotin for Injection, an antibody-drug conjugate developed by Lepu Biopharma. It targets Nectin-4 antigen on nasopharyngeal carcinoma cells and delivers cytotoxic payload to induce tumor cell death. Main IndicationsTreatment of adult patients…
Rhapsido® is the commercial brand name of Remibrutinib Tablets, an orally selective BTK inhibitor developed by BeiGene. It inhibits Bruton’s tyrosine kinase to block abnormal B-cell activation and reduce inflammatory response. Main IndicationsTreatment of adult patients with chronic spontaneous urticaria…
Myqorzo® is the commercial brand name of Aficamten Tablets, an orally selective cardiac myosin inhibitor developed by Cytokinetics and marketed by Sanofi. It reduces excessive myocardial contraction by inhibiting cardiac myosin ATPase activity, relieving cardiac hypertrophy of obstructive hypertrophic cardiomyopathy.…
Inlyta® is the commercial brand name of Axitinib Tablets, an orally selective multi-target VEGFR tyrosine kinase inhibitor developed by Pfizer. It suppresses vascular endothelial growth factor receptor to block tumor angiogenesis and inhibit renal carcinoma proliferation. Main IndicationsTreatment of advanced…
Jakavi® is the commercial brand name of Ruxolitinib Phosphate Tablets, an orally active selective JAK1/JAK2 inhibitor developed by Novartis. It blocks abnormal JAK-STAT signaling pathway to relieve splenomegaly and disease-related symptoms caused by myeloproliferative neoplasms. Main IndicationsTreatment of intermediate or…
Nerlynx® is the commercial brand name of Neratinib Maleate Tablets, an orally active irreversible pan-HER tyrosine kinase inhibitor developed by Puma Biotechnology. It irreversibly inhibits EGFR, HER2 and HER4 to block downstream oncogenic signaling and restrain tumor cell proliferation. Main…
Rujianing® is the commercial brand name of Lerociclib Hydrochloride Tablets, an orally selective CDK4/6 inhibitor co-developed by G1 Therapeutics and Genor Biopharma. It blocks CDK4/6 kinase activity to arrest tumor cell cycle and suppress proliferation of HR-positive breast cancer cells…
Adcetris® is the commercial brand name of Brentuximab Vedotin for Injection, an antibody-drug conjugate developed by Seagen. It binds to CD30 antigen on malignant lymphoma cells and releases cytotoxic agent inside tumor cells to induce cell apoptosis. Main IndicationsTreatment of…
Takhzyro® is the commercial brand name of Lanadelumab Injection, a fully human monoclonal antibody developed by Shire. It selectively binds to plasma kallikrein to inhibit its enzymatic activity, lowering bradykinin overproduction and preventing hereditary angioedema attacks. Main IndicationsRoutine prophylaxis to…
Enhertu® is the commercial brand name of Trastuzumab Deruxtecan for Injection, an antibody-drug conjugate jointly developed by Daiichi-Sankyo and AstraZeneca. It targets HER2 antigen on tumor cell surface to deliver cytotoxic payload into cancer cells and induce tumor cell death.…